Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report
1 Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
2 Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
Cases Journal 2009, 2:121 doi:10.1186/1757-1626-2-121Published: 4 February 2009
Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be a variant of multiple myeloma. It is an aggressive disease with a poor clinical response to standard chemotherapeutic agents.
A novel regimen consisting of bortezomib, doxorubicin, and dexamethasone is currently under active evaluation for the treatment of multiple myeloma. We employed this combination as front-line chemoinduction therapy for a case of primary PCL.
Complete remission was achieved with rapid normalization of hematologic parameters. The combination of bortezomib, doxorubicin and dexamethasone demonstrates promise in the treatment of PCL.